0001104659-24-051581.txt : 20240425 0001104659-24-051581.hdr.sgml : 20240425 20240425071027 ACCESSION NUMBER: 0001104659-24-051581 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240425 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240425 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOOKIPA Pharma Inc. CENTRAL INDEX KEY: 0001760542 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 815395687 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38869 FILM NUMBER: 24872887 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: 0114318906360 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240 CITY: NEW YORK STATE: NY ZIP: 10118 8-K 1 tm2412672d1_8k.htm FORM 8-K
false 0001760542 0001760542 2024-04-25 2024-04-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 25, 2024

 

 

 

HOOKIPA Pharma Inc.

(Exact name of  registrant as specified in its Charter)

 

 

 

Delaware   001-38869   81-5395687

(State or Other Jurisdiction of
Incorporation)

  

(Commission
File Number)

  

(IRS Employer
Identification No.)

 

350 Fifth Avenue, 72nd Floor,

Suite 7240

  
New York, New York   10118
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +43 1 890 63 60

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, $0.0001 par value per share   HOOK   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On April 25, 2024, HOOKIPA Pharma Inc. issued a press release entitled “HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
 No. 		   Description
   
99.1   Press Release, dated April 25, 2024.
   
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 25, 2024 HOOKIPA Pharma Inc.
     
  By: /s/ Joern Aldag
  Name: Joern Aldag
  Title: Chief Executive Officer

 

 

 EX-99.1 2 tm2412672d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

 

·Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback

 

·HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab

 

·Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting

 

·Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below

 

NEW YORK and VIENNA, April 25, 2024 – HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced its final pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab. The Phase 2/3 trial design and protocol are based on alignment with the U.S. Food and Drug Administration (FDA) following the Company’s Type C meeting with the FDA.

 

The seamless Phase 2/3 trial is for the investigational product HB-200 in combination with pembrolizumab for the treatment of patients with Human Papillomavirus 16-positive (HPV16+) recurrent/metastatic PD-L1 CPS ≥ 20 oropharyngeal squamous cell carcinoma (OPSCC) in the first line setting. The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.

 

The Company also announced acceptance of its HB-200 study abstract as an oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in the head and neck cancer session to be held on June 4, 2024. The presentation will include data for approximately 40 head and neck cancer patients treated with HB-200 in combination with pembrolizumab.

 

“It has been a dream of mine—and my HOOKIPA colleagues—to translate our science into a product that will make an impact for patients and help them fight cancer and infectious diseases. I am happy to say that we are taking a very big step forward to making this dream a reality,” said Joern Aldag, Chief Executive Officer of HOOKIPA. “We believe our data is best-in-class and puts us in the lead position for OPSCC in the first line setting. We have alignment with the FDA on our pivotal trial design and protocol, as well as PRIME designation for HB-200 in combination with pembrolizumab for the treatment of patients with OPSCC in the first line setting from the European Medicines Agency. We believe our trial design and alignment with our primary regulators can help us reach a potential registration more quickly. Further, we have been accepted for an oral abstract presentation at ASCO in June 2024 where we will present an update from our Phase 1/2 trial with approximately 40 patients treated with the combination of HB-200 and pembrolizumab.”

 

 

 

HB-200 in combination with pembrolizumab pivotal Phase 2/3 trial design summary

 

·The trial will treat patients with HPV16+ recurrent/metastatic PD-L1 CPS ≥ 20 oropharyngeal squamous cell carcinoma in the first line setting.

 

·The trial is expected to enroll approximately 250 patients across the seamless Phase 2/3 design.

 

·Patients will be randomized one-to-one for HB-200 plus pembrolizumab or placebo plus pembrolizumab.

 

·The primary endpoints are objective response rate for the Phase 2 portion and overall survival for the Phase 3 portion.

 

·The Company may seek accelerated approval based on data from the Phase 2 portion of the trial, from approximately half of the Phase 2/3 study patients, if favorable.

 

·Phase 2 primary analysis expected in 2026 with potential subsequent filing for accelerated approval.

 

The Company will host a conference call today where HOOKIPA’s Executive Team will discuss the full details of the trial design, and the Company’s clinical development strategy for oncology.

 

Call Details:

 

HOOKIPA HB-200 Phase 2/3 Clinical Trial Update

Thursday, April 25, 2024, 8:00 a.m. ET

Webcast Registration

Dial-in Registration

 

Abstract details: ASCO 2024 Annual Meeting

 

HB-200:

Title: HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results

Presenter: Dr. Alan L. Ho, Head and Neck Oncologist at Memorial Sloan Kettering Cancer Center and a trial investigator

Abstract Type: Oral abstract

Session Name: Head and Neck Cancer

Session Date and Time: June 4, 2024; 9:45 AM-12:45 PM CDT

Abstract Number: 6005

 

Title: Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV

Presenter:  Dr. Ari Rosenberg, Principal Investigator, TARGET-HPV Trial, University of Chicago Medicine

Abstract Type: Rapid oral abstract

Session Name: Head and Neck Cancer

Session Date and Time:  June 3, 2024; 8:00 AM-9:30 AM CDT

Abstract Number: 6017

 

 

 

Trial Sponsor: UChicago Medicine

 

HB-700

Title: Development of an arenavirus-based immunotherapy for treatment of KRAS mutant cancer

Abstract Type: Abstract only

Session Date:  May 23, 2024

Abstract Number: e14672

 

About HB-200

 

HB-200 is HOOKIPA’s lead oncology candidate engineered with the company’s proprietary replicating arenaviral vector platform. It comprises two single-vector compounds with arenaviral backbones based on lymphocytic choriomeningitis virus (LCMV) and pichinde virus (PICV). Both express the same transgene encoding an E7E6 fusion protein derived from HPV16. HB-200 is an alternating 2-vector immunotherapy designed to further focus the immune response against the encoded antigen.

 

HB-200 in combination with pembrolizumab received Fast Track Designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency for the treatment of first-line HPV16+ recurrent/metastatic oropharyngeal squamous cell carcinoma. These designations are supported by preliminary clinical evidence from the Phase 1/2, open-label, clinical trial (NCT04180215) evaluating safety, T cell response, and efficacy based on objective response rate (ORR) and disease control rate (DCR) as defined by RECIST 1.1. and iRECIST. As presented at the European Society for Medical Oncology Annual Congress 2023, HB-200 in combination with pembrolizumab showed a 42 percent confirmed ORR and disease control rate DCR of 74 percent across 19 evaluable patients, doubling the 19 percent ORR for pembrolizumab alone.1

 

About HOOKIPA

 

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other unnamed indications. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

 

Find out more about HOOKIPA online at www.hookipapharma.com.

 

1Harrington et al. Pembrolizumab with or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Journal of Clinical Oncology. 2023;41(4);790-802.

 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “will,” “would” or similar expressions and the negative of those terms. Forward-looking statements in this press release include HOOKIPA’s statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, HOOKIPA’s expectations regarding the design and protocol of the Company’s upcoming pivotal Phase 2/3 clinical trial of HB-200 in combination with pembrolizumab, the timing of patient enrollment in clinical trials and the availability of data therefrom, and the timing o submissions concerning regulatory approval, and other statements that are not historical fact. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the risk that results of preclinical studies and clinical trials may not be predictive of future results in preclinical studies or clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see HOOKIPA’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of potential risks, uncertainties and other important factors in HOOKIPA’s subsequent filings with the Securities and Exchange Commission, which are available on the SEC’s website at https://sec.gov and HOOKIPA’s website at http://hookipapharma.com/. In addition, any forward-looking statements represent HOOKIPA’s views only as of today and should not be relied upon as representing its views as of any subsequent date. HOOKIPA explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

 

 

 

Availability of Other Information About HOOKIPA

 

Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.

 

For further information, please contact:

 

Investors and Media

Michael Kaiser

michael.kaiser@hookipapharma.com

+ 1 (917) 984 7537

 

 

 EX-101.SCH 3 hook-20240425.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hook-20240425_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 hook-20240425_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2412672d1_ex99-1img001.jpg GRAPHIC begin 644 tm2412672d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 25, 2024
Entity File Number 001-38869
Entity Registrant Name HOOKIPA Pharma Inc.
Entity Central Index Key 0001760542
Entity Tax Identification Number 81-5395687
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 350 Fifth Avenue, 72nd Floor,
Entity Address, Address Line Two Suite 7240
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10118
City Area Code +43
Local Phone Number 1 890 63 60
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol HOOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://hookipapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hook-20240425.xsd hook-20240425_lab.xml hook-20240425_pre.xml tm2412672d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2412672d1_8k.htm": { "nsprefix": "hook", "nsuri": "http://hookipapharma.com/20240425", "dts": { "schema": { "local": [ "hook-20240425.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hook-20240425_lab.xml" ] }, "presentationLink": { "local": [ "hook-20240425_pre.xml" ] }, "inline": { "local": [ "tm2412672d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://hookipapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2412672d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2412672d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-051581-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-051581-xbrl.zip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tm2412672d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001760542 2024-04-25 2024-04-25 iso4217:USD shares iso4217:USD shares false 0001760542 8-K 2024-04-25 HOOKIPA Pharma Inc. DE 001-38869 81-5395687 350 Fifth Avenue, 72nd Floor, Suite 7240 New York NY 10118 +43 1 890 63 60 false false false false Common Stock, $0.0001 par value per share HOOK NASDAQ true true